Provided by Tiger Trade Technology Pte. Ltd.

GlucoTrack, Inc.

2.26
-0.0150-0.66%
Volume:33.57K
Turnover:76.18K
Market Cap:1.80M
PE:-0.02
High:2.32
Open:2.25
Low:2.20
Close:2.27
52wk High:136.29
52wk Low:2.20
Shares:798.40K
Float Shares:759.70K
Volume Ratio:0.28
T/O Rate:4.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-112.7747
EPS(LYR):-468.2383
ROE:-620.63%
ROA:-164.45%
PB:-1.03
PE(LYR):0.00

Loading ...

GlucoTrack (GCTK) Stock Rallies 16% After Hours: Here's What Is Going On

Benzinga
·
Jul 17

Update – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-controlled Public Platform

THOMSON REUTERS
·
Jul 17

Press Release: Update

Dow Jones
·
Jul 17

Glucotrack - Lokahi Therapeutics Becomes Wholly Owned Subsidiary of Glucotrack - SEC Filing

THOMSON REUTERS
·
Jul 16

Glucotrack - Lokahi Shareholders to Receive 19.99% of Glucotrack Common Stock Outstanding as of Merger Date - SEC Filing

THOMSON REUTERS
·
Jul 16

Glucotrack - Enters Merger Agreement with Lokahi Therapeutics on July 14, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 16

Top Premarket Gainers

MT Newswires Live
·
Jul 15

GlucoTrack, Lokahi Therapeutics Complete Merger

MT Newswires Live
·
Jul 15

YSX Tech Stock Soars 14% After Hours: Here's Why

Benzinga Earnings
·
Jul 15

Glucotrack (GCTK) Stock Is Trending Overnight — Here’s Why it Spiked Over 69% in After-Hours Session

Benzinga_recent_news
·
Jul 15

Glucotrack Names Erik Emerson CEO, Paul Goode CTO in Lōkahi Deal

Reuters
·
Jul 15

Press Release: Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-controlled Public Platform

Dow Jones
·
Jul 15

GlucoTrack announces USPTO notice of allowance for patent application

TIPRANKS
·
Jul 08

Glucotrack Says USPTO Allows Patent Claims for Implantable Continuous Blood Glucose Monitoring Platform

Reuters
·
Jul 08

Glucotrack Announces Uspto Notice of Allowance for Patent Application Covering Its Implantable Cbgm Platform

THOMSON REUTERS
·
Jul 08

GlucoTrack announces 2026 annual shareholder meeting

Reuters
·
Jun 18

GlucoTrack IDE submission enters FDA review for implantable blood glucose monitor

Reuters
·
May 26

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions

GlobeNewswire
·
May 26

GlucoTrack faces Nasdaq delisting over minimum bid price deficiency

Reuters
·
May 16

GlucoTrack's Q1 net loss narrows

Reuters
·
May 15